Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07041723 · ClinicalTrials.gov registry record · NA

BiOfeedback, Online for Sibilant Treatment

A NA study of Speech Sound Disorder, sponsored by Montclair State University.

Recruiting
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT07041723: Recruiting NA study of Speech Sound Disorder, sponsored by Montclair State University.

NCT07041723 is a NA study of Speech Sound Disorder that is actively recruiting participants, run by Montclair State University. The registered enrollment target is 6 participants, below the 89-participant average among 15 other Speech Sound Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07041723, a NA study of Speech Sound Disorder, is actively recruiting participants, sponsored by Montclair State University.

RECRUITING
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate the efficacy of sibilant biofeedback treatment delivered via telepractice in six children ages 8:0-17;11 who present with distortions of /s/. The main questions it aims to answer are: * Primary hypothesis: Biofeedback treatment for sibilants delivered via telepractice will produce positive gains compared to a no-treatment baseline phase. * Secondary hypothesis: Participants will experience positive changes in social-emotional well-being after receiving biofeedback treatment for sibilants as reported by the participants and their guardians. Following the initial evaluation, participants will be randomly assigned to transition from baseline to treatment at one of seven possible points, ranging from 4-10 baseline sessions in which /s/ production will be probed but not treated. All participants will then receive 20, 1-hour biofeedback treatment sessions over 10 weeks with a certified Speech-Language Pathologist via teletherapy, followed by three maintenance sessions.

Primary Outcome

To assess generalization of perceptual training to production, participants will be assessed with standard probes administered in the first three baseline sessions , at the start of each treatment session and in three post-treatment maintenance sessions. Probes will elicit 60 words \[considered the primary target\], containing /s, z/ in various phonetic contexts. Stimuli in each probe will be presented individually in randomized order. No auditory models will be provided; for children with readi

Conditions Studied

Interventions

  • BEHAVIORAL Visual-acoustic biofeedback for Sibilants

Study Locations (1)

New Jersey

  • Montclair State University - Bloomfield

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2025-07-30
Est. Completion 2027-07
Phase NA
Montclair State University

8 total trials

What NCT07041723 shows while recruiting

NCT07041723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 89-participant average among 15 other Speech Sound Disorder trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Speech Sound Disorder appearing as the primary indexed condition, and to 1 intervention - of which Visual-acoustic biofeedback for Sibilants is the first listed.

NCT07041723 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT07041723 about?

NCT07041723 is a clinical study titled "BiOfeedback, Online for Sibilant Treatment". The goal of this clinical trial is to evaluate the efficacy of sibilant biofeedback treatment delivered via telepractice in six children ages 8:0-17;11 who present with distortions of /s/. The main questions it aims to answer are: * Primary hypothesis: Biofeedback treatment for sibilants delivered ...

What is the current status of trial NCT07041723?

This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2025-07-30. Estimated completion is 2027-07.

What conditions does trial NCT07041723 study?

This clinical trial studies the following conditions: Speech Sound Disorder.

What interventions are being tested in trial NCT07041723?

The interventions under investigation include: Visual-acoustic biofeedback for Sibilants (BEHAVIORAL).

Who is sponsoring clinical trial NCT07041723?

This trial is sponsored by Montclair State University, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07041723 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Speech Sound Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07041723's enrollment target sits among peer trials

6 16th of 15 the lowest of 15 other Speech Sound Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Speech Sound Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07041723, the US trial registry maintained by the National Library of Medicine. NCT07041723 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.